Compare Gitlab Inc (GTLB) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gitlab Inc vs Illumina, Inc. — how do they compare? Gitlab Inc trades at $55.07 (market cap $8.92B), while Illumina, Inc. trades at $278.89 (market cap $39.95B). The key difference: Illumina, Inc. is far larger — about 4.5× Gitlab Inc's market cap, and Gitlab Inc is trading nearer its 52-week high, Illumina, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gitlab Inc for 62 Days and Illumina, Inc. for 83 Days on average.
| GTLB | ILMN | |
|---|---|---|
Market Cap | $8.92B | $39.95B |
Volume | 4,716,893 | 3,169,503 |
Sector | Technology | Health |
52-Week High | $53.56 | $293.69 |
52-Week Low | $19.42 | $91.00 |
Typical Hold Time | 62 Days | 83 Days |
Enterprise Value | $7.66B | $41.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GitLab (GTLB) trades at $55.09, up 5.96% today and near its 52-week high, with strong technical momentum. The company shows impressive revenue growth, reaching $759M in 2025, though it remains unprofitable with a net margin of -4.99%. Recent Q2 2026 earnings beat expectations with EPS of $0.24 versus $0.18 expected, driven by AI product traction and sales momentum. Analyst sentiment is mixed with a Hold consensus but positive news flow highlights AI-driven demand and raised guidance.
Outlook: GTLB benefits from AI integration in DevSecOps and strong execution, but high valuation (P/E 521) and persistent losses pose risks. Investment case hinges on sustained revenue growth and path to profitability. Key risks include competitive pressure and reliance on AI adoption trends.
Illumina (ILMN) trades at $278.17, up 3.89% today and near its 52-week high of $278.99. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent inclusion in the S&P 500 and positive analyst upgrades reflect growing institutional confidence. Revenue remains stable at $4.34B for 2025 with improved profitability, delivering $850M net income after previous losses.
The outlook remains positive with sequencing growth and AI initiatives driving momentum, though elevated valuation ratios and China market headwinds present risks. Analyst consensus leans bullish with 54% buy ratings, but the current price exceeds the $241 consensus target, suggesting near-term consolidation potential before further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
